262 related articles for article (PubMed ID: 30888625)
1. Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol.
Woosley RD; Romero K; Heise CW; Gallo T; Tate J; Woosley RL
Drug Saf; 2019 Jul; 42(7):907-913. PubMed ID: 30888625
[TBL] [Abstract][Full Text] [Related]
2. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
3. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
4. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
Poluzzi E; Raschi E; Motola D; Moretti U; De Ponti F
Drug Saf; 2010 Apr; 33(4):303-14. PubMed ID: 20297862
[TBL] [Abstract][Full Text] [Related]
5. Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data.
Kao D; Bucher Bartelson B; Khatri V; Dart R; Mehler PS; Katz D; Krantz MJ
Ann Intern Med; 2013 May; 158(10):735-40. PubMed ID: 23689766
[TBL] [Abstract][Full Text] [Related]
6. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.
Sessler NE; Walker E; Chickballapur H; Kacholakalayil J; Coplan PM
Postgrad Med; 2017 Jan; 129(1):62-68. PubMed ID: 27977317
[TBL] [Abstract][Full Text] [Related]
7. Methadone-associated Q-T interval prolongation and torsades de pointes.
Stringer J; Welsh C; Tommasello A
Am J Health Syst Pharm; 2009 May; 66(9):825-33. PubMed ID: 19386945
[TBL] [Abstract][Full Text] [Related]
8. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
9. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
10. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
Thomas SH; Behr ER
Br J Clin Pharmacol; 2016 Mar; 81(3):420-7. PubMed ID: 26183037
[TBL] [Abstract][Full Text] [Related]
12. QTc interval prolongation associated with intravenous methadone.
Kornick CA; Kilborn MJ; Santiago-Palma J; Schulman G; Thaler HT; Keefe DL; Katchman AN; Pezzullo JC; Ebert SN; Woosley RL; Payne R; Manfredi PL
Pain; 2003 Oct; 105(3):499-506. PubMed ID: 14527710
[TBL] [Abstract][Full Text] [Related]
13. Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.
Swank KA; Wu E; Kortepeter C; McAninch J; Levin RL
J Am Pharm Assoc (2003); 2017; 57(2S):S63-S67. PubMed ID: 28073687
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
Poluzzi E; Raschi E; Moretti U; De Ponti F
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):512-8. PubMed ID: 19358226
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
[No Abstract] [Full Text] [Related]
16. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
17. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
Kao DP; Haigney MC; Mehler PS; Krantz MJ
Addiction; 2015 Sep; 110(9):1468-75. PubMed ID: 26075588
[TBL] [Abstract][Full Text] [Related]
18. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.
Lorberbaum T; Sampson KJ; Woosley RL; Kass RS; Tatonetti NP
Drug Saf; 2016 May; 39(5):433-41. PubMed ID: 26860921
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
20. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]